Cemiplimab for advanced NSCLC: Squamous subgroup analysis from EMPOWER-Lung 1 and 3
Dr Tamta Makharadze, medical oncologist at LTD High Technology Hospital Medical Center at Tbilisi, Georgia presented an exploratory subgroup analysis in patients with squamous NSCLC who were treated with cemiplimab from the EMPOWER-Lung 1 and the EMPOWER-Lung 3 trials. Subgroup analysis with long-term follow-up data demonstrate improved clinical benefit of cemiplimab as firstline monotherapy or in combination with platinum-doublet chemotherapy over chemotherapy alone in patients with squamous NSCLC.
With the educational support of:
 |
 |
 |
 |
 |